Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn

Removes Sanofi Royalty Payments on Brain-Penetrant SAR442168

17 Aug 2020

• By Sten Stovall

Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.

Merger — Sanofi says US biotech buy ‘fully aligned with our R&D priorities.’ • Source: Shutterstock

Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn

Removes Sanofi Royalty Payments on Brain-Penetrant SAR442168

More from Deals

More from Business